계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Therachon
company
About
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $60M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 11 - 50
- Operating Status
- Close
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$100M
Therachon has raised a total of
$100M
in funding over 2 rounds. Their latest funding was raised on
Aug 9, 2018 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 9, 2018 | Series B | $60M | 2 | — | — | Detail |
| Jan 6, 2017 | Series A | $5M | 2 | — | — | Detail |
| Sep 30, 2015 | Series A | $35M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Therachon is funded by 2 investors.
Inserm Transfert Initiative
and Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Inserm Transfert Initiative
|
— | Series B |
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
